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Review Article
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Abstract
Most common drug development failures originate from either bioavailability problems or unexpected toxic effects.
The culprit is often the liver, which is responsible for biotransformation of the majority of xenobiotics. Liver may
be modeled using liver-on-a-chip devices, which may include established cell lines, primary human cells, and stem
cell-derived hepatocyte-like cells. The choice of biological material along with its processing and maintenance greatly
influence both the device performance and the resultant toxicity predictions. Impediments to the development of liver-ona-chip technology include problems with standardization of cells, limitations imposed by culturing, and the necessity to
develop more complicated fluidic contours. Recent breakthroughs in the development of cell-based reporters, including
ones with fluorescent labels, permit monitoring of the behavior of the cells embedded into the liver-on-a-chip devices.
Finally, a set of computational approaches has been developed to model both toxic responses and the homeostasis
of human liver as a whole; these approaches pave the way to enhance the in silico assessment of potential toxicity.

1 Introduction

Drug development is becoming more and more expensive: It
takes 12-15 years and around two billion dollars to bring a single
drug into the market. The current paradigm of drug discovery
relies on high throughput screening (HTS) of chemical libraries
to identify compounds that bind purified target molecules produced by means of genetic engineering (Coussens et al., 2017;
Raucy and Lasker, 2010). Lead compounds identified in HTS in
vitro assays are subjected to secondary screens in established cell
models before proceeding into animal testing. Currently, there is
a substantial push for the development of standardized cell-based
assays compatible with HTS format (Nickischer et al., 2018; Xia
and Wong, 2012) or even the whole-animal assays (Delvecchio et
al., 2011; O’Reilly et al., 2014; Pandey and Nichols, 2011).
Using human-derived cell line-based assays as the secondary
screen has a number of advantages, the most important one
being that cultivated cells are very close in their composition
Received March 22, 2018; Accepted May 22, 2018;
Epub May 28, 2018; © The Authors, 2018.
ALTEX 35(3), 397-412. doi:10.14573/altex.1803221

Correspondence: Ancha Baranova, PhD, School of Systems Biology,
College of Science, George Mason University,
Mail Stop 5B3, 10900 University Blvd, Manassas,
VA 20110-4400, USA
(abaranov@gmu.edu)

ALTEX 35(3), 2018

and metabolite concentrations to the cells in the human body.
This characteristic helps to deprioritize drug candidates that
are incapable of competing with endogenous co-substrates or
co-ligands. Moreover, compounds that are unable to permeate
cell membranes or that display direct toxicities would be also
eliminated. However, work with the cell-line based models has
a fundamental shortcoming: the human body is built from many
hundreds of cell types, while commonly established cell cultures
are typically homogenous.
One way to bridge this gap is to perform secondary screens in
cell types representing the tissues most commonly contributing
to the systemic toxicity that may arise when the whole body is
exposed to a novel pharmaceutical. The culprit is often the liver,
which is responsible for biotransformation of the majority of xenobiotics. Direct toxicity to the hepatic parenchyma is also quite
common. Historically, approximately 20-30% of all drug withdrawals from US and EU markets are due to hepatotoxicity, with
drug-induced liver injury (DILI) contributing at least 40% to the
This is an Open Access article distributed under the terms of the Creative Commons
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited.
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number of withdrawals in the United States (Olson et al., 2000;
Peters, 2005). Ideally, potential drug toxicities should be discovered during preclinical testing in cellular or animal models. Nevertheless, many drugs were found to cause injury to human liver
only after marketing and were subsequently either discontinued
or received the warning label. Whether the failure of preclinical
modeling is due to human genetic variants, immune reactions or
disease-related metabolic problems, the animal models are limited in detecting human-specific phenomena. In addition, there is
also a strong push to minimize the use of animal models due to
ethical concerns (Langley et al., 2015).
Therefore, in this review we concentrate on liver cell-based
platforms amenable to standardizing for their eventual use in
toxicity screening compatible with HTS mode. This goal can be
achieved with the development of liver-on-a-chip devices with
embedded human cells. Such platforms may be useful both at
the earliest steps of drug development (Fig. 1), which embraces
the paradigm of “failing early-failing cheaply”, and at later development stages, where they will eventually reduce the use of
animals and provide more human-relevant information.
2 Human liver metabolism differs from that
of animals

Liver is an intricate factory built by a variety of cooperating cells
that perform over 500 distinct functions, including large scale

synthesis of various blood components, metabolism of glucose,
fatty acids and cholesterol, production of bile, and detoxification/
biotransformation of endogenous and exogenous substances. Of
all the important liver functions, its metabolism – especially that
of pharmaceutical drugs and other xenobiotics – is perhaps the
most important in the context of pharmaceutical toxicology. In
hepatic parenchyma, xenobiotics undergo three phases of metabolism and transport: (1) Phase I, which is mainly catalyzed by
the cytochrome P450 enzymes (CYP450) and results in transformation of lipophilic compounds into water-soluble metabolites;
(2) Phase II, where various enzymes conjugate xenobiotics and/
or their metabolites to highly polar molecules such as glucose,
glucuronic acid, sulfate, or glutathione; (3) Phase III, where
specific or non-specific transporters efflux these highly polar
metabolites out of hepatocytes into the bile, or release them back
to the blood for subsequent excretion with urine. The extreme
diversity of the Phase I/II enzymatic system is a root cause for
poor predictive performance of cell-based hepatotoxicity assays
for possible adverse effects of potential drugs in humans.
Although Phase I reactions may be carried out by any combination of 50 cytochrome P450 (CYP450) monooxygenases,
some of these enzymes are more important than others. Six
cytochromes, namely CYP1A2, CYP2C9, CYP2C19, CYP2D6,
CYP3A4, and CYP3A5, are capable of metabolizing 90% of
known drugs (Liddle and Stedman, 2007; Lynch and Price,
2007). Both the isoenzyme profile of these cytochromes and the
relative catalytic activity within a particular source of the liver

Fig. 1: HTS-based drug discovery paradigm
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Tab. 1: Comparison of cell sources for liver-on-a-chip technology
Cell source

Primary
hepatocytes
(Bell et al., 2017;
Hart et al., 2010)

Upcyte ®

HepG2

Differentiated
HepaRG
(Bell et al., 2017;
Gerets et al., 2012;
Hart et al., 2010;
Le Vee M. et al.,
2006)

iPSC derived

(Ramachandran
et al., 2015b;
Herzog et al., 2016;
Schaefer et al.,
2016, 2018)

(Gerets et al., 2012;
Hart et al., 2010)

Genetic
similarity
to human
hepatocytes

Exact (derived
from particular
individual)

Exact (derived
from particular
individual)

Medium
(derived from
hepatoblastoma
with abnormal
karyotype and
highly malignant
phenotype)

High (quiescent,
differentiated
cancer cell line with
stable sub-diploid
karyotype with
minimal alterations)

Exact (derived
from particular
individual)

Variability

High

Low

High

Low

High

Standardization

Impossible

Possible

Impossible

Possible

Impossible

Use in
personalized
medicine

Yes

No

No

No

Yes

Supply

Limited

Unlimited

Unlimited

Relatively unlimited

Unlimited

Viability

10-14 days

10-14 days

7 days

30 days

2-4 days

Number of
passages

n/a

40

Unlimited

20 to preclude
instability

50

Functional
stability

Yes

Yes

No

Yes

Unknown

P450 enzymatic
profile

1A2, 2A6, 2C8,
2B6, 2C19, 2C8,
2D6, 2E1, 2C9,
3A4, 3A5, 3A7

1A2, 2C8, 2B6,
2C19, 2C9, 2D6,
3A4

1A2, 2C8, 2B6,
2C9, 3A5, 3A7

1A2, 2A6, 2B6,
2C19, 2C8, 2E1,
2D6, 2C9, 3A4,
3A5, 3A7

1A2, 2A6, 2B6,
2C19, 2C8, 2E1,
2D6, 2C9, 3A4,
3A5, 3A7

Total P450
activity

High

Low

Low

Medium

Relatively low, as in
fetal hepatocytes

Transporters

ABCBA, ABCB7,
ABCF3, ABCB1,
ABCC1, ABCC2,
ABCC3, ABCE1,
ABCF1, ABCF2,
GTR1, SLCO1B1,
SLC22A1

ABCF3, ABCB1,
ABCC1, ABCC2,
ABCE1, ABCF1,
ABCF2, GTR1,
ABCB11,
SLCO1B1,
SLC22A1,
SLC47A1

ABCF3, ABCB1,
ABCC1, ABCE1,
ABCF1, ABCF2,
GTR1

ABCBA, ABCB7,
ABCF3, ABCB1,
ABCB11, ABCC1,
ABCC2, ABCC3,
ABCE1, ABCF1,
ABCF2, GTR1,
SLC22A1,
SLCO2B1,
SLCO1B1,
SLC10A1

ABCBA, ABCB7,
ABCF3, ABCB1,
ABCB11, ABCC1,
ABCC2, ABCE1,
ABCF1, ABCF2,
GTR1, SLC10A1

Generation of
reporter lines

Impossible

Possible

Possible

Possible with
limitations

Possible

(relevant
references)

material are most critical for the standardization and for proper
functioning of the liver-on-a-chip device.
Phases I and II are commonly referred to as “metabolic detoxification,” which is a misnomer, as many xenobiotics are metabolized into either bioactive or toxic compounds. Recapitulation
of the in vitro liver drug metabolism is the pivotal aim of a liveron-a-chip development. Ideally, preclinical assays would require
use of highly standardized cellular components; at the end, the
potencies and other characteristics of various drugs should be
ALTEX 35(3), 2018

(Baxter et al.,
2015;
Chaudhari et al.,
2016)

compared one to another across the batches of disposable devices. The easiest way to standardize biological components
of the chip without reverting to cell immortalization is to use
cells prepared from inbred animals, for example, a particular
strain of mice. Unfortunately, the comparison of the content of
nine CYP450 enzymes in the microsomes derived from hepatic
specimens procured from mouse, rat, rabbit, dog, micropig and
monkey revealed that no single model species resembles the
enzyme activities in human liver (Bogaards et al., 2000). More399
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over, the metabolic abilities of Phase II enzymes also markedly
differ among species as was demonstrated for UDP-glucuronosyltransferase (UGT) activity (Hanioka et al., 2016) as well as for
sulfation and glutathione conjugation (Miller et al., 1993).
Therefore, we would have to create liver chips using cells of
human origin to best predict human liver metabolism. Let us
consider how close different preparations of liver cells may resemble human liver (Tab. 1).
3 Liver cells and cell lines: available choices

Liver slices and whole perfused organs preserve an intact tissue
structure, thereby being the most physiologically realistic model.
However, their standardization and long-term maintenance have
proven close to impossible. However, some reliable approximation of the liver could be achieved with the aid of microfabrication and advanced tissue engineering, capable of the generation
of “on-a-chip” tissue and organ models suitable for HTS purposes. Of note, these models can be imaging- and analysis-friendly
as they allow for real-time monitoring of the state of the living
cells and their extracellular environment. A successful platform
for mimicking liver physiology and hepatic drug metabolism
in vitro is expected to replicate all major liver functions by
controlling cellular dynamics over a prolonged period of time,
which is currently defined as more than 28 days.
3.1 Hepatocytes
Human hepatocytes represent nearly 60% of the total cell population within the liver. These cells, capable of performing a
majority of liver functions, can be isolated from the human liver
via collagenase perfusion. Primary hepatocytes are commonly
accepted as the “gold standard” for constructing liver models
for drug testing and other applications. Maintaining an in vivo-like phenotype for isolated hepatocytes is challenging, since
in a monolayer culture these cells undergo significant changes
in Phase I and II metabolism and lose function over 72 hours
(Rodriquez-Antona et al., 2002). Moreover, cultured primary
hepatocytes may also lose their polarization, which would, in
turn, greatly affect their ability to efflux biotransformed compounds (Luttringer et al., 2002; Noel et al., 2013). Luckily, both
the widely used well-differentiated human hepatoma cell line
HepaRG and primary human hepatocytes retain their polarization even in monolayers, as is evident by differential expression
of a proper set of influx and efflux transporters at their sinusoidal
and canalicular poles, respectively (Le Vee et al., 2013, 2015).
The functional life of hepatocytes may be prolonged by a variety of techniques. One promising approach is to culture them
as spheroids, through inhibiting hepatocyte attachment to vessel
walls and, thereby, enforcing their floating as aggregates. Spheroids may be formed by mechanical agitation by rotary shaker
or spinner flask, hanging drop or using non-adherent surface
chemistry. Hepatocellular spheroids retain a majority of the parenchymal functions, including the secretion of albumin, urea,
transferrin and bile, along with Phase I and II biotransformation

activity, for at least three weeks after seeding (Arakawa et al.,
2017), which make them suitable for cytochrome induction tests.
Hepatocyte spheroids are compatible with a serum-free medium
and co-culturing with non-parenchymal Kupffer, stellate and
biliary cells (Bell et al., 2016). Heterotypic spheroids reflect
tissue environments in vivo, and, at least theoretically, permit
construction of larger tissue models by higher order assembly
of individual spheroids. In composite spheroids, i.e., spheroids
composed of collagen microparticle scaffolds and cells, the
optimal ratio of hepatocytes to type I collagen microparticles
is approximately 1:1; the shift towards more of the collagen
microparticles compromises hepatocyte functions (Yamada et
al., 2015). On the other hand, an optimal co-culturing ratio for
hepatocytes supported with endothelial progenitor cells is 5:1,
in the presence of alginate-collagen (Chan et al., 2016). Another
recent work used a 3D printing technique to combine alginate
hydrogels with primary hepatocytes and mesenchymal stem
cells (MSCs). This approach improved the viability of isolated
hepatocytes to more than 90% and their morphological stability
to up to 7 days (Kim et al., 2018).
Another hepatic modeling approach is based on sandwich
cultures, also known as overlays. Sandwiching hepatocytes
between two layers of ECM leads to formation of “plate” structures similar to the in vivo liver anatomy. The planar structure of
the sandwich allows easy microscopic imaging. This technique
preserves the polarity, including basal surfaces induced by ECM
layers and apical surfaces by cell-to-cell contact, and leads to
the development of a canalicular network and the secretion of
bile (Swift et al., 2010). In sandwich cultures, the viable period
may be increased to up to 6-8 weeks. However, sandwiched
hepatocytes maintain their biotransformation activities and the
ability to induce many Phase I and Phase II enzymes for the first
two 2 weeks only.
Culturing primary hepatocytes within 3D structures formed
by porous poly(L-lactide-co-glycolide) (PLGA) modified type I
collagen nanofibers that mimic the natural liver environment is a
promising strategy to improve the synthetic function of the liver
cells over time (Brown et al., 2018).
In a recent study, primary human hepatocytes grown in a sandwich overlaid with extracellular matrix were directly compared
to 3D spheroids in repeated-dose toxicity studies using 5 different liver toxins. To ensure robustness of the findings, the study
was performed in six different laboratories using cryopreserved
cells collected from the same set of donors. The study showed
superiority of the 3D spheroids in expression of ADME-related
proteins, as well as in catalytic activities of five different cytochromes (Bell et al., 2018).
3.2 Upcyte ® hepatocytes
The upcyte® (“upregulated”) technology involves virus-guided
introduction of a unique combination of genes that induce and
maintain cell proliferation until the cells reach confluence. This
allows the primary cells to be passaged many times with the
generation of billions of cells. Human upcyte® hepatocytes1 are
primary human hepatocytes derived by transducing E6 and E7

1 http://www.upcyte.technologies.com
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proteins of human papillomaviruses, which release hepatocytes
from cell cycle arrest and allow their proliferation in response
to oncostatin M (OSM), a member of the interleukin-6 (IL-6)
superfamily involved in liver regeneration. In cultures, upcyte®
hepatocytes undergo a finite number of cell divisions without
being immortalized or losing adult primary cell phenotype
(Burkard et al., 2012). Upon stimulation with OSM, doubling
time for these cells is between 33 and 49 hours. After OSM
is withdrawn, upcyte® hepatocytes differentiate to generate
highly functional cells. This method allows expanding human
hepatocytes for 35 population doublings, resulting in 1015 (a
quadrillion) cells from each liver biopsy. Over 12 billion upcyte® hepatocytes can be generated from one vial of primary
human hepatocytes, thus meeting the high demand for standardized cells necessary for HTS studies. In the first-generation
upcyte® hepatocytes, cytochromes CYP1A2, CYP2B6, and
CYP3A4, but not CYP2B6, were drug-inducible at the mRNA
level, suggesting the necessity for additional optimization. Second-generation upcyte® hepatocytes (Levy et al., 2015) form
metabolically functional, polarized cultures with functional bile
canaliculi and expression profiles for nuclear receptors, Phase I
and II enzymes, and drug transporter genes comparable to those
in primary human hepatocytes. As with the first-generation upcyte® hepatocytes, second-generation cells lack fetal markers
and express cytokeratin 8 and 18, human serum albumin and
store glycogen (Levy et al., 2015).
Upcyte® technology opens new horizons in modeling organotypic cultures. In a recent report, functional 3D hepatic
structures were generated using a defined mixture of three types
of differentiated human upcyte® cells, namely hepatocytes,
liver sinusoidal endothelial cells (LSECs) and mesenchymal
stem cells (MSCs). When all three types of cells were plated
on a thick layer of Matrigel™, they self-organized to form liver
organoid-like structures within 24 hours; during a 10 day culturing in a bioreactor, these liver organoids showed typical functional characteristics of liver parenchyma including activity of
CYP3A4, CYP2B6 and CYP2C9 as well as mRNA expression
of several marker genes and other enzymes (Ramachandran et
al., 2015a).
It is also important to note that upcyte® hepatocytes can be
transformed with reporter constructs to permit real time monitoring of hepatocyte functions and/or drug effects.
3.3 HepG2 cells
The HepG2 cell line was derived from a hepatocellular carcinoma of a 15-year-old Caucasian male. Due to low endogenous
expression of cytochromes, HepG2 cells are a relatively poor
choice for detection of hepatotoxicity (Wilkening et al., 2003)
(Tab. 1). Even when HepG2 cells are made to express cytochromes forcibly, via adenoviral transfection, these cells do not
reach liver model standards, as they also lack activity of aldolase
B; several drug transporters such as BSEP, OATP-C, NTCP, and
OCT-1; and a range of non-cytochrome Phase II enzymes, such
as GSTA 1/2 and GSTM1 (Gripon et al., 2002; Guillouzo et al.,
2007; Wilkening et al., 2003).

ALTEX 35(3), 2018

Historically, HepG2 cells were extensively exploited to
examine cytoprotective, antioxidative, hepatoprotective, anti-hepatoma, hypocholesterolemic, anti-steatosis, bioenergetic
homeostatic and anti-insulin resistant properties of various bioactive compounds of chemical and botanical origin (Kaur et al.,
2018). Due to high content of organelles and mtDNA, HepG2
cells remain a model of choice for investigation of mitochondrial
toxicity through evaluations of mitochondrial fragmentation, lysosome content and mitophagy as well as mitochondrial release
of cytochrome c, leading to apoptosis and/or necrosis (Paech et
al., 2018; Paemanee et al., 2017). Because of that, attempts to
improve the overall performance of HepG2 are continued, with
the chief strategy to overcome their limitations being the development of three dimensional (3D) models, including co-culturing (He et al., 2018) and generation of the spheroids maintained
in the hanging drops or otherwise (Hurrell et al., 2018; Shah et
al., 2018).
3.4 HepaRG cells
Although the HepaRG cell line was derived from a hepatoma
of a female patient with cirrhosis following hepatitis C virus
infection (Gripon et al., 2002), unlike other human liver cell
lines, HepaRG cells express many drug processing genes at levels similar to those in primary human hepatocytes. In particular,
HepaRG express various nuclear receptors, transporters, and
specific markers of adult hepatocytes (albumin, haptoglobins,
and aldolase B) (Guillouzo et al., 2007). In confluent cultures,
HepaRG cells differentiate from a stem cell/progenitor state to
mature hepatocytes and primitive biliary cells and maintain a
relatively stable function for several weeks (Jossé et al., 2008).
HepaRG cells, including 3D-organotypic HepaRG cultures
obtained using a scaffold-free, high-throughput hanging drop
system are considered a viable option for evaluating hepatotoxic
chemicals with reproducible responses (Gunness et al., 2013).
A high-throughput transcriptional profiling of both differentiated and undifferentiated HepaRG cells found that these cells
have much higher resemblance to primary human hepatocytes
and biopsied livers that HepG2 (Hart et al., 2010). These transcriptomics data have been recently supported by proteomics:
a global proteomic analysis of HepG2, upcyte®, and HepaRG
showed that the cytochrome activity levels of both HepG2 and
upcyte® were reduced by 90% in comparison to primary hepatocytes, while levels in HepaRG cells were reduced by 60%
(Sison-Young et al., 2015). Remarkably, HepaRG cells also retained expression of MRP3 and P-gp (MDR1) transporters.
Molecular profiling data described above indicate that the
HepaRG cell line in many ways resembles human primary
hepatocytes, which is encouraging for utilization of these cells
in the studies of xenobiotic metabolism, hepatotoxicology, and
hepatocyte differentiation. It is, however, important to note that
HepaRG cells eliminate galactose/sorbitol and produce albumin
at rates higher than in primary hepatocytes, while being unable
to excrete urea (Lübberstedt et al., 2011). As HepaRG cells are
a clone derived from a particular individual, it is not surprising
that the levels of cytochrome activities and their relative induc-
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ibility in these cells match some primary hepatocyte cultures but
not others (Berger et al., 2016; Hart et al., 2010; Lübberstedt et
al., 2011; Sison-Young et al., 2015). These differences are most
likely intrinsic as they reflect variation in the expression levels
of individual cytochromes across healthy humans.
3.5 Induced pluripotent stem cells (iPSC)
Induced pluripotent stem cell (iPSC) technology was introduced
in 2006 (Takahashi and Yamanaka, 2006). iPSCs originate from
adult cells reprogrammed by the introduction of several genes
essential for embryonic stemness, namely Oct3/4, Sox2, c-Myc,
and Klf4. Similar to embryonic stem cells, iPSCs can be differentiated into endoderm, mesoderm or ectoderm. This technology has important implications for drug toxicology (Anson
et al., 2011). In particular, utilization of iPSCs in drug testing
addresses the main problems arising from utilization of primary
cells, such as limited quantities, donor to donor variation and
relatively short lifespan in vitro, and circumvents ethical requirements since these cells do not come from embryos (Shafritz et
al., 2009). iPSCs allow construction of surrogate liver panels to
represent the most common combinations of Phase II enzyme
variants and, therefore, to evaluate the potential of adverse drug
reactions in the population and to provide an additional step towards the personalization of medicine. Thus, iPSCs may help
to identify the potential for idiosyncratic hepatotoxicity, which
may develop in some patients but not others – something which
may be missed in the course of typical hepatotoxicity studies.
Since 2009, when the first protocol for the production of iPSC
derived hepatocyte-like cells was published (Song et al., 2009),
a variety of optimizing modifications to the standard procedure
were proposed (Chen et al., 2012; Chin et al., 2009; Huang et
al., 2014; Liu et al., 2010; Schwartz et al., 2014; Si-Tayeb et
al., 2010; Takayama et al., 2012). Remarkably, some of these
modifications simplified the workflow: instead of differentiating
the cells in the presence of serum supplemented with growth factors and small metabolites, the protocols shifted towards greater
standardization, with elimination of primary feeder cell requirements and introducing serum-free media.
iPSC-derived hepatocyte-like cells maintain a majority of
hepatocytic functions, including the production of albumin,
expression of cytochromes, and the storage of glycogen, while
displaying global expression profiles resembling those of primary human hepatocytes (Gao and Liu, 2017). However, transcriptomic analyses revealed that for certain functional gene
sets, the expression patterns of iPSC and of cultured primary
hepatocytes differ substantially, with genes related to endocytosis upregulated (Bell et al., 2017), and cytochrome production
downregulated (Bell et al., 2017; Si-Tayeb et al., 2010). Another
aspect that limits wide utilization of iPSCs in drug testing is the
standardization issue. The genetics of each iPSC line reflect the
genetics of its donor. Consequently, iPSC lines differ in their
epigenetic profiles, miRNA patterns and differentiation properties (Chin et al., 2009; Marchetto et al., 2009; Miura et al.,
2009), which greatly contribute to lab-to-lab variations typically
observed in toxicological studies. Furthermore, the efficiency of
iPSC differentiation into hepatocytes is at 60% and even when
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best protocols are used (Chistiakov and Chistiakov, 2012) deriving the line requires expensive and time consuming extraction
and purification steps.
To overcome the mentioned limitations, Cellular Dynamics
International (CDI) has developed 95% pure iPSC derived iCell®
Hepatocytes, which are claimed to closely resemble primary
cells. However, a recent comparative study of these cells along
with HepaRG and human hepatocyte co-cultures showed that
their metabolic activity is more than tenfold lower and approximates that of HepG2 (Kratochwil et al., 2017). This regretful
outcome stresses the importance of keeping an eye on a “Holy
Grail” of iPSC-based cellular modeling: a resemblance between
the naturally differentiated cells residing within the body and
forcefully differentiated cells produced from iPSCs.
One way to make sure that the produced cells perform adequately is to compare their expression profiles with those of naturally differentiated cells using CellNet, a computational platform
which evaluates the extent to which cell- and tissue-specific
gene regulatory networks are established under one or another
differentiation protocol (Cahan et al., 2014; Radley et al., 2017).
When correctly assessed for the resemblance of their target cell
type, iPSC-derived hepatocyte-like cells may become a valuable
tool for personalized toxicology and metabolism studies.
4 Cell line standardization problem

An induction of liver-on-a-chip technology into the main aisle
of toxicology labs is critically dependent on our ability to standardize the cells seeded on to the chip. In principle, cell standardization requires the stability and reproducibility of the four
main characteristics: (a) Viability for prolonged periods of time,
which may be assessed via fluorescence imaging techniques
that rely on a combination of nuclear and cytosolic dyes; (b) the
retention of a toxicologically-relevant metabolic profile with stable activity of Phase I and Phase II enzymes; (c) drug transporter
activity, which should be taken into consideration during initial
vetting of an in vitro platform for studies of drug metabolism;
(d) secretory capacity, which is approximated by albumin biosynthesis and urea excretion. Notably, a consistently high albumin production at levels of approximately ~1-5 μg per 106 cells
per hour serves as an indispensable indicator of the overall metabolic health of the cells; urea plays a similar role for evaluating
general metabolic capacity. To directly detect albumin secreted
by hepatocyte culture, 3D scaffold-based immunoassay chips
have been developed recently (Yan et al., 2015).
As can be seen from Table 1, the standardization requirements
are fulfilled only by upcyte® and HepaRG cells, with HepaRG
being even closer in their cytochrome and transporter profiles
to primary hepatocytes than the upcyte® cultures. To fully standardize the cell behavior in the liver-on-a-chip devices, there is
a need to collect data to evaluate their response to exposure to
a panel of at least 100 drugs, roughly divided into four categories that include safe and efficacious, safe and non-efficacious,
non-safe and efficacious, and non-safe and non-efficacious compounds, all with well characterized in vivo metabolism. More-
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over, each drug has to be studied in a range of concentrations to
determine both acute and chronic effects. In other words, both
IC50/LD50 and a variety of the biomarkers of functional impairment have to be assessed.
5 Limitations imposed by culturing

Until recently, liver cell monocultures were a mainstay of toxicology practice for a number of well-defined “fit-for-purpose”
assays. Nowadays, it is widely recognized that single cell type
monolayers do not reflect the complexity of a tissue developed
within a living organism. The limitations of hepatocyte monoculture are obvious. One of the most promising approaches to
overcome the issues with viability of hepatocyte monoculture
is the utilization of microfluidic perfusion devices (Knöspel et
al., 2016; Shulman and Nahmias, 2013; Tehranirokh et al., 2013;
Wagner et al., 2013). Unfortunately, for a majority of cell types,
the cultivation period still does not exceed 14 days. Recently,
Klein et al. (2014) demonstrated that HepaRG cells can be
maintained in optimized serum-free media for 30 days without
a decline in their viability. This finding certainly opens up the
opportunity for the use of these cells in systems toxicology.
Both viability and functioning of hepatocytes are reduced in
the absence of non-parenchymal cells. These supportive cells
include fibroblasts, endothelial cells, stellate and Kupffer cells,
and biliary epithelial cells (Ries et al., 2000; Soto-Gutierrez et
al., 2010). Importantly, the addition of even one type of auxiliary
cell often helps. For example, Okamoto et al. (1998) developed
a co-culture system of primary human hepatocytes with the hepatic stellate cell line LI90, which retains a substantial activity
of P450 cytochromes for at least 2 weeks, however, no rescue
of urea excretion was noted. In another study, primary human
hepatocytes were co-cultured with human umbilical vein endothelial cells (HUVEC) to achieve marked improvement of albumin production, urea biosynthesis and the rate of diazepam biotransformation (Salerno et al., 2011). Kostadinova et al. (2013)
developed a 3D mixed culture of primary hepatocytes with a
variety of non-parenchymal cell types. This liver-like culture
maintained the production of albumin, fibrinogen, transferrin
and urea for up to 3 months, while retaining the ability to induce
the synthesis of cytochrome P450 on a drug exposure cue.
From the standpoint of liver biology, non-homotypic cultures
have a better chance to correctly predict drug-induced liver injury as its development often depends on the communication
between hepatocytes and the resident macrophages, which,
upon exposure to certain drug metabolites, may be activated
to serve as intrahepatic sources of inflammation (Endo et al.,
2012; Kegel et al., 2015). Indeed, previously mentioned 3D
liver equivalents containing a variety of non-parenchymal cells,
including Kupffer macrophages, already demonstrated their
value in the detection of potential inducers of idiosyncratic liver
injury (Kostadinova et al., 2013). Similar results were obtained
for micropatterned co-cultures containing either primary human
hepatocytes or iPSC-derived hepatocytes and murine fibroblasts
(Ware et al., 2015).
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It is important to note that hepatocyte-produced drug metabolites may be non-toxic for liver cells while exerting adverse
effects on other organs and tissues. To address this problem, several heterotypic cell cultures have been developed. For example,
a microfluidic-based platform for co-culture of neurospheres and
liver equivalents was recently employed in a two-week assay
involving repeated exposure to the neurotoxin 2,5-hexanedione.
It showed a significantly higher sensitivity compared to either
hepatocyte or neurosphere monocultures (Materne et al., 2015).
The same group also developed a platform for co-culture of liver
organoids with skin (Wagner et al., 2013). On a microfluidic chip
for the co-culture of HepaRG and kidney cells (MDCK) created by another group (Choucha-Snouber et al., 2013), a 3-day
exposure to ifosfamide led to the detection of apparent nephrotoxic effects, while no toxicity was observed in monocultured
MDCKs. In spheroid co-culture of HepaRG with primary human
hepatic stellate cells (HSCs), exposure to pro-fibrotic compounds
allowed the detection of multiple fibrotic features such as HSC
activation, collagen secretion and deposition, thereby providing
an avenue for in vitro testing of possible contributors to liver
fibrosis (Leite et al., 2016).
6 The way to improve hardware

The need for better detection and instrumentation, as well as better materials, stems from the need to pump controlled microliter
volumes of medium through the chip circuits and, in particular,
to distribute the flow at critical junctions with a high degree of
precision. Most scientists agree that devices of 100 μm in height
or less are preferable since at that scale they approach the diameter of the liver sinusoids, which is in the order of 5-10 μm. At this
height, the problems with the signal and/or metabolite dilution
that plague larger-scale platforms are reduced.
Interpretation of the data generated with the aid of a microfluidic device critically depends on correct scaling of the physical
and physiological parameters and on the relevance of the selected computational model of drug response and toxicity. One of
the most important parameters that control the adsorption, distribution, metabolism, excretion and toxicity (ADMET) in physiological systems is the exposure time of the tissue to drugs and
other xenobiotics, which is called the organ-specific transit time.
According to an initial model generated in 1963 after experimentation on dogs, liver-specific transit time is between 10 and
20 seconds (Goresky, 1963). However, later studies demonstrated that in humans the hepatic transit time is substantially longer,
from minutes to hours (Chiou, 1983). Moreover, hepatic transit
time depends on the structure of a compound (Chiou, 1983) and
may vary between individuals, being influenced by their genetics
and overall state of health (Pedersen et al., 2005). Accordingly,
to mimic in vivo ADMET characteristics in the fluidic systems,
one has to have an ability to adjust fluidic residence times to the
required physiological values.
To evaluate drug metabolite-induced toxicity, more complicated fluidic systems are necessary (Fig. 2) (Marx et al., 2016).
Multi-parametric evaluation of the drug effects may include the
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Fig. 2: Microfluidic platform for long-term multi-tissue coculture with closed circuit

studies of intestinal permeability, biotransformation pathways,
as well as tests for the toxicity of a drug and its metabolites
(Semenova et al., 2016; Zakhariants et al., 2016). Employing a
combination of different cell types that reflect tissue-tissue interactions observed in whole organisms could significantly add to
the value of the collected data. However, the disadvantages of
multi-cell type devices stem from their underlying complexity
and include low throughput and questionable scalability.
Detection in the microfluidic platforms is a challenge. In order
to capture both acute and chronic effects of exposure to drugs,
toxins or environmental factors, successful liver-on-a-chip
devices should sum and present the data stream collected in real-time. On top of that, due to cell to cell differences observed
in all types of culture, quantitative monitoring of intracellular
changes and cell-cell interactions should be performed on a per
cell basis, rather than in bulk. Growing trends of single-cell
transcriptomics and biochip compatible reporters, are, in part,
catering to this need.
One of the approaches to explore intracellular changes might
be microRNA level monitoring in the culture medium of the
microfluidic platform. MicroRNA (miRNA) is a class of small
non-coding RNAs that mediate post-transcriptional gene silencing by sequence-specific inhibition of the target mRNAs’
translation and/or lowering their half-lives in the cytoplasm
(Turchinovich et al., 2015, 2016). Together with their binding
partners, Argonaute proteins, miRNAs form cores of RNA-induced silencing complexes. Finally, the discovery of cell-free
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miRNAs in all biological fluids suggests that miRNAs might
also act as signaling molecules outside the cell, and may be utilized as biomarkers (Makarova et al., 2014, 2016).
To monitor the state of the hepatocyte cell culture, both hepatocyte-specific microRNAs (miR-122) and miRNA species highly
expressed in the liver (miR-21, miR-19a/b, miR-106a/b) may be
employed. The change in the representation of these microRNAs
in the culture medium may be utilized for sensing a physiological
change in the hepatocytes under the influence of the studied compound. Also, a number of microRNAs affecting the expression
of ADMET genes were discovered. So, for example, miR-27b
and miR-378 (Mohri et al., 2010) regulate the expression of cytochromes 1B1, 2E1 and 3A4. The appearance of such microRNAs
in the microfluidic system cell culture medium may thus significantly affect the functional capacity of the device.
Metabolomics presents yet another, very interesting alternative
for extracting quantitative information about the dynamic metabolic response of the modelled liver to pathophysiological conditions. In two recent studies, the metabolite profiles of HepG2
cells treated with various test substances were analyzed to reveal concentration-response effects mapped to a variety of the
response patterns consistent with different liver toxicity mechanisms (García-Cañaveras et al., 2016; Ramirez et al., 2018).
On the other hand, the spatiotemporal dynamics of the multicellular milieu could be monitored with the aid of a small
fluorescent molecule (probe) or a protein-based fluorescent biosensor. In this respect, reporter cells have great promise; such
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Fig. 3: Luciferase fusion reporter concept in the case of NRF2

cells natively fluoresce upon stimulation or under certain stress
conditions, thus revealing specific information about the state
of the cell. Optical interrogation of the hepatocyte culture with
integrated “sensor” cells engineered to respond to particular signals may provide a way to extract this type of information in a
real-time format.
7 Biochip compatible reporter assays

One of the most important modern trends in drug discovery is
the switch from the “one disease – one target” mentality to the
understanding that diseases are driven by shifts in a homeostatic
balance. Even the smallest of these changes may involve many
interacting genes and proteins upstream and downstream of a
malfunctioning element in a biological puzzle. Hence, the focus
of the HTS efforts has also shifted toward a search for various
modulators which exert their action either through fine-tuning
various transcription factors, or by controlling epigenetics landscapes. Cell-based reporter-enabled biochips are ideally suited
for the purpose of HTS for activators and inhibitors of transcription factors. Reporters with fluorescent labels are preferable for
use on the liver-on-a-chip devices, since they permit monitoring of the reporter response in intact cells. However, the recent
development of a cell-permeable reagent for Renilla luciferase
(Lindberg et al., 2013) opens the possibility of measuring luminescence within the intact cells.
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The choice of reporter constructs for transforming hepatocyte-like cell lines is wide (Tab. 1). In particular, classic promoter-based reporters comprised of a fluorescent or luminescent
protein gene under the promoter of a gene of interest, are readily
available from commercial sources. Such promoter-based reporters are useful for monitoring of expression, and have been
recently employed to monitor activation of CYP genes in HepG2
and HepaRG cells (Tsuji et al., 2014). The chief disadvantage
of these reporters is their relatively low level of signal, which
is often detected with a substantial delay due to the time necessary for promoter activation, transcription and translation of
the reporter protein. Another problem is that many genes require
for proper expression either relatively large promoter regions or
even the presence of distant enhancers, which cannot be spliced
into the plasmid- or virus-based reporter construct due to size
limitation. This limitation could be surmounted by using bacterial artificial chromosome (BAC) transgene-based cell lines with
very large, locus-wide holding capacity inclusive to all regulatory elements ensuring the normal physiological regulation of a
fluorescent or luciferase reporter expression (Poser et al., 2008).
The Bscl2-GFP and Srxn1-GFP BAC reporter assays were successfully employed to differentiate between two different types
of response to genotoxic agents in many stably transfected cell
lines (Hendriks et al., 2012). Recently, the feasibility of the
BAC-reporter approach has been evaluated by testing the effect
of over 2000 FDA approved drugs and active natural product
compounds on the modulation of the Srxn1-GFP reporter in
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HepG2 cells (Wink et al., 2014). Integration of BAC-reporters
into the cell component of the liver-on-a-chip devices is expected in the nearest future. The most current panel of BAC-GFP
modified HepG2 cells, each complete with an upstream sensor,
downstream transcription factor and their respective target gene,
include reporters for the oxidative stress response pathway
(Keap1/Nrf2/Srxn1), the unfolded protein response in the endoplasmic reticulum (Xbp1/Atf4/BiP/Chop), and the DNA damage
response (53bp1/p53/p21) (Wink et al., 2017).
Another way to overcome the size limitation obstacle is to
use a fusion-based reporter, which, typically, is comprised of
either fluorescent or luminescent protein label enjoined with a
full-size protein of interest expressed under a constitutive promoter, for example, pcmv. These reporters permit monitoring the
half-life and the trafficking of the protein in the living cell. The
overwhelming problem with these types of reporters is that the
fused protein is fully physiologically active and is often capable
of disturbing the intracellular balance, thus triggering an expression of the downstream genes and significantly shifting the
transcriptomic and proteomic profile of the cells. In turn, these
shifts reflect upon the efficacy and toxicity profiles obtained for
the drugs under study. Another drawback of the fusion systems
is that the promoter is constitutively active, often leading to
overexpression of the construct over the physiological limits and
resultant perturbation of cell homeostasis.
Yet another type of reporter has been developed for the monitoring of transcription factors regulated by ubiquitination and
proteasomal degradation. The concept for these reporters is
shown in Figure 3. In a nutshell, it is a fusion where a luminescent or fluorescent label is added to an isolated ubiquitination
machinery recognition domain instead of a complete target
protein. As the recognition domain has no affinity for DNA, it
does not activate the specific program regulated by a particular
transcription factor, even when overexpressed. There is still a
possibility that overexpression of the recognition domain may
serve as a decoy for ubiquitination machinery, hence, to at least
some degree, stabilizing the endogenously expressed transcription factor, but these effects are usually negligible.
Among transcription factors regulated by ubiquitination and
proteasomal degradation, there are three which are directly relevant to monitoring performance of hepatocytes embedded into
liver-on-a-chip devices. These are the transcription factors Nrf2,
HIF (hypoxia inducible factor), and NF-κB.
7.1 Nrf2
Nrf2 (nuclear factor erythroid 2-related factor 2) orchestrates
the antioxidant response by inducing the expression of cytoprotective, pro-survival proteins such as thioredoxin reductase,
glutathione reductase, glutathione S-transferase (GST), hemeoxygenase-1 (HO1), catalase and others. Under homeostatic conditions, Nrf2 is sequestered by binding to its inhibitory protein,
Keap1 (Kelch-like ECH-associated protein-1). Keap1 serves as
a bridge between Nrf2 and the Cul3-Rbx1 E3 ubiquitin ligase,
which permits polyubiquitination of the lysines positioned within
the central α-helix of the Neh2 recognition domain. As a result of
oxidative/electrophilic stress, active cysteines of Keap1 are mod-
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ified, and Nrf2 protein is released for subsequent translocation to
the nucleus, where it induces expression from the promoters with
the antioxidant response elements (ARE) (Kaspar et al., 2009).
Importantly, Nrf2 is constitutively active in many primary tumors (de la Vega et al., 2016). Hence, it is not surprising
that tumor-derived HepG2 and HepaRG cells overexpress
Nrf2-regulated genes. Upcyte® cultures do that too, however,
to a lesser degree (Sison-Young et al., 2015). When HepaRG
were compared to upcyte® cells, peroxiredoxin-1 and -2, thioredoxin reductase and thioredoxin were found to be overexpressed
substantially (Sison-Young et al., 2015), indicating that HepaRG
cells are protected against effects of the drugs causing glutathione depletion. In other words, drug toxicity estimates obtained
while working with HepaRG or HepG2 tend to be a bit more
optimistic than they should be.
A reporter for monitoring Nrf2 activation, Neh2-luc (Smirnova et al., 2011), permits the real time monitoring right after addition, with no lag-period, while being 10-fold more sensitive
than ARE-luc reporters (Smirnova et al., 2011). This reporter has
already found its use in the discovery labs, especially when an
estimate of the intracellular alkylating power of a drug is needed.
Neh2-luc enabled screening of drug libraries showed that at least
10% of all compounds behave as non-specific Nrf2 activators,
meaning that they may alkylate active protein and peptide thiols
in general, and glutathione in particular. In other words, administration of these drugs actively shifts the cellular redox balance
and triggers the adaptive response. It is expected that Neh2-derived reporter will be fitted with a fluorescent label compatible
with liver-on-a-chip devices.
7.2 HIF
HIF, a transcription factor capable of activating a battery of
genes involved in glucose uptake and metabolism, extracellular
pH control, angiogenesis, erythropoiesis, mitogenesis, and apoptosis, is expressed ubiquitously. It consists of 2 subunits, known
as HIF1-α and HIF1-β. The levels of HIF1-α are regulated by hydroxylation of its Pro564 and/or 402 residues. This modification
serves as a prerequisite for interaction with the tumor suppressor
von Hippel-Lindau (VHL) protein, yielding a complex that provides for a rapid HIF ubiquitination and degradation (see review
(Kaelin, 2005) and references therein). HIF hydroxylation is
executed by the so-called HIF prolyl hydroxylases represented
by 3 isozymes. Upregulation of HIF is an indication of the low
oxygen supply and the enactment of the Warburg effect, a metabolic shift towards glycolysis.
A luc-reporter with ODD (oxygen degradable domain) of HIF
has been developed (Safran et al., 2006) and its variant with
Renilla luciferase has just become commercially available from
Promega. In HTS, employment of HIF1 ODD-luc reporter allowed an identification of the hit with excellent neuroprotective
properties later confirmed in hemorrhagic stroke models in vivo
(Smirnova et al., 2010; Karuppagounder et al., 2016). Such a
reporter might also be utilized for evaluation of substrate specificity of HIF prolyl hydroxylase isoforms and structure-activity
relationship studies (Osipyants et al., 2017; Poloznikov et al.,
2017; Smirnova et al., 2017). This fact clearly demonstrates
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superior properties of novel generation of cell-based reporters
with respect to drug development. In liver-on-a-chip devices, in
addition to drug discovery purposes, the reporter can be used to
quantitate hypoxia and HIF activation. In hypoxia (or with HIF1
activation by other means), expression of cytochromes P450
and Phase II enzymes is down-regulated. This metabolic feature
principally affects drug toxicity profiles; this is especially true
for drugs developed for oncological treatment. Under hypoxia,
HepaRG cells have been shown to display metabolic changes
similar to those observed in poorly differentiated hepatocarcinomas; therefore, these cells may serve as a suitable in vitro model
for testing of anticancer agents in hypoxic versus normoxic conditions (Legendre et al., 2009).
7.3 NF-κB
NF-κB (nuclear factor kappa-light-chain-enhancer of activated
B cells) controls both the inflammatory cytokine production and
the survival of cells. In an inactive state, NF-κB is complexed
with the inhibitory protein IκBα. Activation of IκB kinase (IKK)
results in phosphorylation of IκBα protein, and its subsequent
ubiquitination, which leads to dissociation of IκBα from NF-κB
and eventual degradation of IκBα by the proteasome. The activated NF-κB is then translocated into the nucleus. Inhibiting
NF-κB signaling has a potential for the treatment of cancers
and inflammatory diseases. Importantly, persistant activation
of NF-κB, which is known as chronic inflammation, is known
to be a component of idiosyncratic hepatotoxicity (Jiang et
al., 2017). Currently, there is no cell-based reporter to monitor
NF-κB activation directly. However, a reporter monitoring degradation of its inhibitory partner IκBα can be constructed under
the same principle as Neh2- and HIF ODD-derived reporters.
The IκBα-derived reporter can be used for drug discovery and
for assessing drug toxicity, similarly to other reporters of this
kind, with a special value for studying idiosyncratic hepatotoxicity in assays of controllably activated NF-κB.
8 In silico modelling of liver function

There has been significant progress in developing the liver-ona-chip and other liver-emulating technologies. However, the
field is still somewhat in its infancy in terms of the standards,
procedures and methods for translating the data obtained in vitro
into reliable predictions applicable to human body responses. In
parallel to various in vitro efforts, the development of predictive
computational models of hepatic metabolism is also under way.
Although many models perform quite well on the datasets they
were developed on, they sometimes suffer from low statistical
performance, with imbalanced sensitivity vs specificity ratios.
Speaking generally, the predictive power of any computational model heavily depends on the quality of the respective
training data set. When machine learning approaches are used,
bigger datasets are preferable to smaller ones. The frameworks
of large-scale screening programs, e.g., Tox21, already allowed
the development of prediction models with an accuracy as
high as 86.9%, sensitivity of 82.5%, and specificity of 92.9%
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(Capuzzi et al., 2016; Chen et al., 2012). On the other hand, the
larger the dataset is, the higher the chance of mislabeling either
the chemical structures or their toxicity classes. Consequently,
manual trimming of large datasets may lead to improvement of
model precision. To expand availability of highly confident data,
industry-driven collaborative efforts are required. One example
of such efforts is the eTOX project, which is comprised of a
database filled with unpublished toxicology reports donated by
13 members of the pharmaceutical industry along with public
toxicology data, and its customizable interface eTOXsys (Sanz
et al., 2015). The models developed in the course of the eTOX
project are available as possible augmentations for higher-level
predictors. In one recent study, the models for BSEP, BCRP,
P-glycoprotein and for OATP1B1 and 1B3 were investigated for
their potential to improve the DILI-predicting algorithm. Surprisingly, in this particular case, an integration of the transporter-related data did not significantly improve the performance of
the resultant model (Kotsampasakou et al., 2017).
There are some interesting attempts to model the liver “as a
whole”, with the homeostasis or the “starting state” of the liver
being described by a set of differential equations, which can
be modified as a reflection of the respective change observed
under certain disease conditions and immunological states. This
approach treats hepatotoxicity as a complex outcome of the
factors at play, which includes the genotype of the patient, the
drugs he or she is exposed to, and any underlying diseases, for
example, steatosis. An example of this type of systemic model
would be a VirtualLiver, developed by Strand Life Sciences,
which couples equations describing the kinetics of biochemical
pathways involved in liver homeostasis with those obtained after
collection of a set of in vitro measurements quantifying various
drug-induced perturbations (Subramanian et al., 2008). Clearly, this type of approach describes the biological system better
than any endpoint analysis of toxicity, as it is able to reflect a
steady accumulation of changes which eventually culminate in
reaching an irreversible outcome. The development of holistic
in silico models that simulate the metabolism of the liver is a
necessary step towards an adequate and timely assessment of
various chemical entities, natural or synthetic.
9 Conclusion

In this review, we describe the current approaches to develop
liver-on-a-chip devices for the prediction of the liver toxicity in
humans. These devices may include established immortal cell
lines, for example, HepG2 – a “workhorse” of liver toxicology –
or its less malignant counterpart HepaRG, unmodified or modified primary human cells, and stem cell-derived hepatocyte-like
cells, or iPSC. Like many technologies developing on the interface of applied biology and bioengineering, the liver-on-a-chip
devices were started in an attempt to produce a “one-fits-all”
solution, but eventually ended facing a variety of important dilemmas. In particular, the choice of biological material greatly
influences both the performance of the devices and the precision
of the toxicity reports. Unfortunately, unavoidable manipulations
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with the living component of the chip lead to activation of the
Nrf2 and NF-κB-dependent transcriptional programs, which, in
turn, reflect upon the cellular response to environmental stressors. Among other impediments to the development of liver-on-achip technology are the problems with standardization of cells,
limitations imposed by culturing, and the necessity to develop
more complicated fluidic contours. Fortunately, recent breakthroughs in the development of cell-based reporters, including
ones with fluorescent labels, permit monitoring the behavior of
the cells embedded into the liver-on-a-chip devices. Finally, a set
of computational approaches has been developed to model both
toxic response pathways and the homeostasis of human liver as
a whole; these approaches pave the way to enhance the in silico
stage of assessment of potential toxicity.
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